Posted by Michael Wonder on 21 Jan 2025
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama
20 January 2025 - Teva Pharmaceuticals will semi-exclusively market FYB203 under the brand name Ahzantive in major parts of Europe.
Formycon and its licensing partner Klinge Biopharma today jointly announce that the European Commission has granted central marketing authorisation for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama.
